Crossmark

Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective

Crossref DOI link: https://doi.org/10.1186/s13561-024-00588-2

Published Online: 2025-01-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yu, Cuicui

Wu, Yingqi

Geng, Yadi

Yan, Hui

Zhu, Pengli

Ji, Peng

Wu, Fei

Ning, Lijuan

Feng, Yubin

Shen, Aizong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (52273308)
License Information

Text and Data Mining valid from 2025-01-10

Version of Record valid from 2025-01-10
More Information

Article History

Received: 19 December 2023

Accepted: 16 December 2024

First Online: 10 January 2025

Declarations

:

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below